Faculty
Cynthia Ma.jpg

Cynthia X. Ma, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Pharmacogenomics of anticancer agents
  • Predictive biomarkers
  • Developmental therapeutics

Contact

  • 314-362-9383 (tel)
  • 314-362-7086 (fax)
  • 4515 McKinley Research Building, Room 3311 (office)
  • Division of Oncology
    Campus Box 8076
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Articles

  • Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer
    Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H, Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN
    Clin Cancer Res 2017 Mar 29; [Epub ahead of print]
  • Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 trial (Alliance)
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K
    J Clin Oncol 2017 Apr 1;35(10):1061-1069
  • Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
    Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyo D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L
    Nat Commun 2017 Mar 28;8:14864
  • 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer
    Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS
    Clin Cancer Res 2017 Mar 15; [Epub ahead of print]
  • NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer
    Ma CX, Gao F, Luo J, Northfelt DW, Goetz MP, Forero A, Hoog J, Naughton MJ, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday TJ, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee M, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Huang Bartlett C, Koehler M, Al-Kateb H, Sanati S, Ellis MJ
    Clin Cancer Res 2017 Mar 7; [Epub ahead of print]
  • Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians
    Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX
    Breast Cancer Res Treat 2017 Feb;161(3):491-499
  • Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
    Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX
    Oncotarget 2016 Aug 30;7(35):56864-56875
  • Chemotherapy principles of managing stage IV breast cancer in the United States
    Hernandez-Aya LF, Ma CX
    Chin Clin Oncol 2016 Jun;5(3):42
  • Improving response to hormone therapy in breast cancer: new targets, new therapeutic options
    Rugo HS, Vidula N, Ma C
    Am Soc Clin Oncol Educ Book 2016;35:e40-54
  • Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer
    Ma CX, Bose R, Ellis MJ
    Adv Exp Med Biol 2016;882:125-54
  • A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ
    Clin Cancer Res 2016 Jun 1;22(11):2650-8
  • A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer
    Ma CX, Luo J, Naughton M, Ademuyiwa F, Suresh R, Griffith M, Griffith OL, Skidmore ZL, Spies NC, Ramu A, Trani L, Pluard T, Nagaraj G, Thomas S, Guo Z, Hoog J, Han J, Mardis E, Lockhart AC, Ellis MJ
    Clin Cancer Res 2016 Apr 1;22(7):1583-91
  • The feasibility of using metacognitive strategy training to improve cognitive performance and neural connectivity in women with chemotherapy-induced cognitive impairment
    Wolf TJ, Doherty M, Kallogjeri D, Coalson RS, Nicklaus J, Ma CX, Schlaggar BL, Piccirillo J
    Oncology 2016;91(3):143-152
  • HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor
    Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ
    J Natl Compr Canc Netw 2015 Sep;13(9):1061-4
  • The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer
    Suman VJ, Ellis MJ, Ma CX
    Chin Clin Oncol 2015 Sep;4(3):34
  • Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer
    Napoli N, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R
    Pharmacogenet Genomics 2015 Aug;25(8):377-381
  • Cognitive impairment after chemotherapy related to atypical network architecture for executive control
    Piccirillo JF, Hardin FM, Nicklaus J, Kallogjeri D, Wilson M, Ma CX, Coalson RS, Shimony J, Schlaggar BL
    Oncology 2015;88(6):360-8
  • US breast cancer mortality trends in young women according to race
    Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ
    Cancer 2015 May 1;121(9):1469-76
  • Management of premenopausal women with neoadjuvant endocrine therapy: a single-institution experience
    Barbie TU, Ma C, Margenthaler JA
    Ann Surg Oncol 2015 Nov;22(12):3861-5
  • Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
    Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE
    J Clin Oncol 2015 Jan 20;33(3):265-71
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer - CALGB 40302 (Alliance)
    Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA
    J Clin Oncol 2014 Dec 10;32(35):3959-66
  • A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer
    Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE
    Clin Cancer Res 2014 Dec 1;20(23):5964-75
  • Body mass index, diabetes, and triple-negative breast cancer prognosis
    Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX
    Breast Cancer Res Treat 2014 Jul;146(1):189-97
  • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, Deschryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ
    Cell Rep 2013 Sep 26;4(6):1116-30
  • Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models
    Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX
    Mol Cancer Ther 2013 Aug;12(8):1665-75
  • Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer
    Napoli N, Rastelli A, Ma C, Yarramaneni J, Vattikutti S, Moskowitz G, Giri T, Mueller C, Kulkarny V, Qualls C, Ellis M, Armamento-Villareal R
    Bone 2013 Aug;55(2):309-14
  • A phase I trial of the IGF-1R antibody cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
    Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF
    Breast Cancer Res Treat 2013 May;139(1):145-53
  • Racial differences in outcomes of triple-negative breast cancer
    Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX
    Breast Cancer Res Treat 2013 Feb;138(1):281-9
  • A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Lockhart AC, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM
    Breast Cancer Res Treat 2013 Jan;137(2):483-92
  • Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ
    Cancer Discov 2013 Feb;3(2):224-37
  • Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: challenges and considerations
    Nagaraj G, Ma CX
    J Natl Compr Canc Netw 2013 Mar 1;11(3):246-51
  • Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOS(hi) T cells
    Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, Gao F, Gillanders WE, Mohanakumar T
    Breast Cancer Res Treat 2013 Feb;138(1):109-18
  • Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
    Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, Aft RL, Ellis MJ, Piwnica-Worms H
    J Clin Invest 2012 Apr 2;122(4):1541-52
  • TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
    Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP
    J Clin Oncol 2012 Jul 20;30(21):2615-23
  • Phase II trial of temsirolimus in patients with metastatic breast cancer
    Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ
    Breast Cancer Res Treat 2012 Nov;136(2):355-63
  • Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response
    Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA
    Ann Surg Oncol 2012 Jan;19(1):253-8
  • A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H
    Cancer Chemother Pharmacol 2011 Jun;67(6):1225-37
  • Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
    Sanchez CG*, Ma CX*, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ (*equal contribution)
    Breast Cancer Res 2011 Mar 1;13(2):R21
  • Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner
    Beitelshees AL, Johnson JA, Hames ML, Gong Y, Cooper-Dehoff RM, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL
    PLoS One 2010 Dec 10;5(12):e15180
  • High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer
    Napoli N, Vattikuti S, Ma C, Rastelli A, Rayani A, Donepudi R, Asadfard M, Yarramaneni J, Ellis M, Armamento-Villareal R
    Breast J 2010 Nov;16(6):609-16
  • Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
    Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K
    Lancet Oncol 2010 May;11(5):421-8
  • A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 Consortium study
    Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C
    Cancer 2010 Jul 15;116(14):3463-8
  • Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
    Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR
    J Thorac Oncol 2008 May;3(5):516-20
  • A comprehensive examination of CYP19 variation and breast density
    Olson JE, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Ingle JN, Wu Y, Couch F, Sellers TA, Weinshilboum RM, Vachon CM
    Cancer Epidemiol Biomarkers Prev 2007 Mar;16(3):623-5
  • A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
    Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Wu Y, Couch FJ, Vachon CM, Sellers TA, Weinshilboum RM
    Breast Cancer Res Treat 2007 Apr;102(2):237-47
  • A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA
    Cancer Chemother Pharmacol 2007 Feb;59(2):207-15
  • A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA
    Ann Oncol 2006 Feb;17(2):226-31
  • Human aromatase: gene resequencing and functional genomics
    Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, Eckloff BW, Schaid D, Wieben ED, Adjei AA, Weinshilboum RM
    Cancer Res 2005 Dec 1;65(23):11071-82
  • Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA
    J Clin Oncol 2005 Sep 1;23(25):5929-37
  • Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome
    Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C
    Mayo Clin Proc 2005 Jan;80(1):116-20
  • Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA
    Blood 2004 Jul 1;104(1):40-2
  • Imatinib mesylate-induced interstitial pneumonitis
    Ma CX, Hobday TJ, Jett JR
    Mayo Clin Proc 2003 Dec;78(12):1578-9
  • Recognition of multiple patterns of DNA sites by Drosophila homeodomain protein Bicoid
    Yuan D, Ma X, Ma J
    J Biochem (Tokyo) 1999 Apr;125(4):809-17
  • Contributions to gene activation by multiple functions of Bicoid
    Ma X, Yuan D, Scarborough T, Ma J
    Biochem J 1999 Mar 1;338 ( Pt 2):447-55
  • The Drosophila morphogenetic protein Bicoid binds DNA cooperatively
    Ma X, Yuan D, Diepold K, Scarborough T, Ma J
    Development 1996 Apr;122(4):1195-206
  • Sequences outside the homeodomain of bicoid are required for protein-protein interaction
    Yuan D, Ma X, Ma J
    J Biol Chem 1996 Aug 30;271(35):21660-5